Epizyme, Eisai and Roche to Develop EZH2 Companion Diagnostic
- Collaboration Focused on Genetically Defined Lymphomas -
CAMBRIDGE, Mass., Jan. 7, 2013
CAMBRIDGE, Mass., Jan. 7, 2013 /PRNewswire/ -- Epizyme, Inc., a
biopharmaceutical company leading the creation of personalized therapeutics to
treat patients with genetically defined cancers, Eisai Co., Ltd. (ESALY) and
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a collaboration to develop
an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test.
The collaboration's goal is to identify lymphoma patients with non-wild type
EZH2, including the Y641 mutation. As demonstrated in Epizyme's Nature
Chemical Biology publication, "A selective inhibitor of EZH2 blocks H3K27
methylation and kills mutant lymphoma cells [link]," lymphomas with genetic
alterations of EZH2 require EZH2 enzymatic activity for proliferation,
suggesting that EZH2 is a driving oncogene in these cancers and therefore an
important therapeutic target.
Robert Gould, Ph.D., President and CEO of Epizyme, added, "Epizyme is
committed to the creation and commercialization of personalized therapeutics
and companion diagnostics for patients with genetically defined cancers. Our
collaboration with Roche to develop a companion diagnostic, in parallel with
the clinical development of our EZH2 inhibitor with Eisai, demonstrates our
commitment to accelerate the development of this innovative personalized
therapeutic for lymphoma patients."
"Eisai and Epizyme are collaborating to develop an EZH2 inhibitor as a
personalized therapeutic for patients with genetically defined cancers,"
commented Takashi Owa, Ph.D., Chief Innovation Officer, Eisai Product Creation
Systems. "Working together with Roche enables us to target this important
potential therapeutic for a genetically defined subset of lymphoma patients
with high unmet need."
"Our collaboration with Epizyme and Eisai highlights Roche's position as the
partner of choice for the development and commercialization of companion
diagnostics for personalized healthcare. We are excited to be developing a
diagnostic test that will support Epizyme and Eisai in the development of an
EZH2 inhibitor as a new therapeutic for patients with genetically defined
lymphomas," said Paul Brown, Head of Roche Molecular Diagnostics.
About Epizyme, Inc.
Epizyme is leading the creation of small molecule histone methyltransferase
inhibitors (HMTi), a new class of personalized therapeutics for patients with
genetically defined cancers. Genetic alterations in HMTs, a class of
epigenetic enzymes, drive multiple human diseases. Our approach represents the
future of healthcare by matching better medicines with the right patients.
Epizyme has benchmark alliances with Celgene, GSK and Eisai and receives
funding and strategic support from the Multiple Myeloma Research Foundation
(MMRF) and the Leukemia & Lymphoma Society (LLS). For more information, visit
SOURCE Epizyme, Inc.
Contact: Megan Lustig, Spectrum, +1-202-955-6222 ext. 2586,
Press spacebar to pause and continue. Press esc to stop.